Equities Analysts Offer Predictions for ITOS FY2024 Earnings

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Equities research analysts at Wedbush increased their FY2024 earnings per share estimates for shares of iTeos Therapeutics in a note issued to investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will earn ($3.26) per share for the year, up from their prior estimate of ($3.53). Wedbush currently has a “Outperform” rating and a $25.00 target price on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.64) per share. Wedbush also issued estimates for iTeos Therapeutics’ Q4 2024 earnings at ($0.95) EPS, Q1 2025 earnings at ($1.01) EPS, Q2 2025 earnings at ($1.13) EPS, Q3 2025 earnings at ($1.19) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($4.56) EPS, FY2026 earnings at ($5.26) EPS, FY2027 earnings at ($4.54) EPS and FY2028 earnings at ($1.26) EPS.

Other equities analysts also recently issued research reports about the stock. Wells Fargo & Company assumed coverage on shares of iTeos Therapeutics in a report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 price target for the company. JPMorgan Chase & Co. dropped their target price on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Finally, HC Wainwright reissued a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a research note on Friday.

iTeos Therapeutics Price Performance

Shares of ITOS stock opened at $8.23 on Friday. The business’s fifty day moving average price is $10.40 and its 200 day moving average price is $13.99. The firm has a market capitalization of $300.64 million, a PE ratio of -2.69 and a beta of 1.39. iTeos Therapeutics has a 1-year low of $7.99 and a 1-year high of $18.75.

Hedge Funds Weigh In On iTeos Therapeutics

Several hedge funds have recently bought and sold shares of the stock. nVerses Capital LLC boosted its stake in shares of iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after acquiring an additional 1,700 shares during the last quarter. Point72 DIFC Ltd purchased a new position in iTeos Therapeutics in the 3rd quarter valued at about $31,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of iTeos Therapeutics by 60.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after purchasing an additional 2,646 shares during the last quarter. Quest Partners LLC grew its holdings in shares of iTeos Therapeutics by 914.7% during the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after buying an additional 9,934 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in shares of iTeos Therapeutics by 6.6% in the second quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock valued at $164,000 after buying an additional 690 shares during the last quarter. Hedge funds and other institutional investors own 97.16% of the company’s stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.